Former EMA head to advise NDA Group business

Thomas Lönngren joins new European regulatory and market access business

Independent consultancy the NDA Group has launched NDA Advisory Services, a regulatory and market access business to be based in London, UK that aims to cut the rising cost of new medicines and address the challenges of drug regulation and reimbursement, to ensure that new medicines can get to patients faster.

Thomas Lönngren, previously executive director of the European Medicines Agency (EMA), will take a strategic advisory role in the new business.

The organisation said NDA’s Advisory Board would be integral integral to NDA Advisory Services and will be expanded to include HTA and market access capabilities.

New specialists are to join the Advisory Board to advise pharmaceutical companies on how they can prove the value of their products to national agencies.

Lönngren will play a fundamental role in the new business, building on 30 years’ experience in the regulatory field including the last 10 years heading EMA. One of his key ambitions is to create a co-ordinated approach to Health Technology Assessment and improve market access in Europe.

‘I’ve recognised for a long time that the whole area of market access needs new ideas and a new vision,’ he said.

‘I plan to further develop my ideas surrounding International Regulatory Strategies, coupled with pushing for a joined-up approach to HTA, to enable the best medicines to reach needy patients as efficiently as possible.’

NDA has offices in Germany, Sweden and the UK.

You may also like

Regulatory

ECHA adds two hazardous chemicals to list of substances of very high concern

Companies are responsible for managing the risks of these chemicals and giving customers and consumers information on their safe use
Regulatory

NHS, MHRA and Medicines UK launch Project Revive to tackle medicine shortages

NHS England, the MHRA and Medicines UK have launched Project Revive, a collaborative pilot designed to address critical medicines shortages by fast-tracking dormant MHRA-approved licences and creating dedicated NHS purchasing arrangements to improve long-term supply resilience
Regulatory

En Carta Diagnostics bags FDA Breakthrough Device Designation for EC Pocket Lyme test

The rapid, Point-of-Need molecular diagnostic platform will fill a critical gap in early-stage detection of Borrelia bacteria, the cause of Lyme disease
Regulatory

testo Saveris 1 update automates environmental monitoring workflows for pharma compliance

Testo Saveris, global leader in measurement solutions, has announced the latest software update for its testo Saveris 1 Environmental Monitoring System, designed to address the evolving needs of the pharmaceutical industry by delivering reliable and precise monitoring of key metrics, including temperature and humidity
Regulatory

FDA accepts first quality control standard for mesenchymal stromal cells

The FDA has accepted the first dedicated quality control protocol for mesenchymal stromal cells, recognising the Tasly 3P Characterisation Assay and setting a new regulatory benchmark for MSC safety and clinical performance
Regulatory

3PBIOVIAN secures French CIR certification for Spain and Finland R&D sites

The CDMO has obtained French Crédit d’Impôt Recherche (CIR) certification for its Pamplona and Turku sites, enabling French partners to access tax incentives when collaborating on recombinant protein and advanced therapy projects
Regulatory

Shilpa Medicare targets US approval for extended-release Ondansetron injection for CINV

Shilpa Medicare plans to pursue US approval and licensing partners for OERIS after a Phase III study in India met all primary and secondary endpoints and showed a strong safety profile in chemotherapy-induced nausea and vomiting
Subscribe now